Login to Your Account

Venous infers: Early work sufficient to attract $21M for Ilkos' leg ulcers effort

By Randy Osborne
Staff Writer

Tuesday, September 27, 2016

"The beauty of this deal is that it's not just an out-licensing deal from Servier," CTI Life Sciences partner Jean-François Leprince told BioWorld Today as he explained newly formed Ilkos Therapeutics Inc., which made its debut with a $21 million three-way investment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription